Top

Published in:

01-06-2016 | Original Article

MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus

Authors: Renata Hezova, Alena Kovarikova, Josef Srovnal, Milada Zemanova, Tomas Harustiak, Jiri Ehrmann, Marian Hajduch, Milana Sachlova, Marek Svoboda, Ondrej Slaby

Published in: Tumor Biology | Issue 6/2016

Abstract

Esophageal cancer is a malignant disease with poor prognosis, increasing incidence, and ineffective treatment options. MicroRNAs are post-transcriptional regulators of gene expression involved in many biological processes including carcinogenesis. We determined miR-205 expression levels in tumor/non-tumor tissues of 45 esophageal cancer patients using qPCR and found that decreased level of miR-205 in tumor tissue correlates with poor overall survival in esophageal adenocarcinoma patients. Further, we observed significantly higher levels of miR-205 in tumor tissue of esophageal squamous cell carcinoma. Ectopic overexpression of miR-205 in adenocarcinoma cell line SK-GT-4 led to decreased cell proliferation, cell cycle arrest in G1, and decreased migration ability. Conversely, in squamous cell line KYSE-150, same effects like inhibition of proliferation, migration, and colony-forming potential and cell cycle arrest in G2 were observed after silencing of miR-205. We performed global gene expression profiling and revealed that suppressive functioning of miR-205 in adenocarcinoma could be realized through regulation of epithelial-mesenchymal transition (EMT), whereas oncogenic in squamous cell carcinoma by regulation of metalloproteinase 10. Our results suggest that miR-205 could serve as biomarker in esophageal cancer and acts as a tumor suppressor in esophageal adenocarcinoma and oncogene in esophageal squamous cell carcinoma.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed

Shah MA, Kurtz RC. Upper gastrointestinal cancer predisposition syndromes. Hematol Oncol Clin North Am. 2010;24:815–35.CrossRefPubMed

Blot WJ. Esophageal cancer trends and risk factors. Semin Oncol. 1994;21:403–10.PubMed

Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:5062–7.CrossRef

Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:3719–25.CrossRef

van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefPubMed

Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257–61.CrossRefPubMedPubMedCentral

Orang AV, Safaralizadeh R, Hosseinpour Feizi MA. Insights into the diverse roles of mir-205 in human cancers. Asian Pac J Cancer Prev APJCP. 2014;15:577–83.CrossRefPubMed

Zhao BS, Liu SG, Wang TY, Ji YH, Qi B, Tao YP, et al. Screening of microRNA in patients with esophageal cancer at same tumor node metastasis stage with different prognoses. Asian Pacific J Cancer Prev APJCP. 2013;14:139–43.CrossRef

10.

Matsushima K, Isomoto H, Yamaguchi N, Inoue N, Machida H, Nakayama T, et al. Mirna-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells. J Transl Med. 2011;9:30.CrossRefPubMedPubMedCentral

11.

Fassan M, Volinia S, Palatini J, Pizzi M, Fernandez-Cymering C, Balistreri M, et al. MicroRNA expression profiling in the histological subtypes of Barrett’s metaplasia. Clin Trans Gastro. 2013;4:e34.CrossRef

12.

Saad R, Chen Z, Zhu S, Jia P, Zhao Z, Washington MK, et al. Deciphering the unique microRNA signature in human esophageal adenocarcinoma. PLoS One. 2013;8:e64463.CrossRefPubMedPubMedCentral

13.

Wu X, Ajani JA, Gu J, Chang DW, Tan W, Hildebrandt MA, et al. Microrna expression signatures during malignant progression from Barrett’s esophagus to esophageal adenocarcinoma. Cancer Prev Res. 2013;6:196–205.CrossRef

14.

Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The mir-200 family and mir-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593–601.CrossRefPubMed

15.

Wiklund ED, Bramsen JB, Hulf T, Dyrskjot L, Ramanathan R, Hansen TB, et al. Coordinated epigenetic repression of the mir-200 family and mir-205 in invasive bladder cancer. Int J J Int du cancer. 2011;128:1327–34.CrossRef

16.

Babak T, Zhang W, Morris Q, Blencowe BJ, Hughes TR. Probing micrornas with microarrays: tissue specificity and functional inference. RNA. 2004;10:1813–9.CrossRefPubMedPubMedCentral

17.

Wang D, Qiu C, Zhang H, Wang J, Cui Q, Yin Y. Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets. PloS one. 2010;5.

18.

Zhang B, Pan X, Cobb GP, Anderson TA. Micrornas as oncogenes and tumor suppressors. Dev Biol. 2007;302:1–12.CrossRefPubMed

19.

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microrna molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189–98.CrossRefPubMed

20.

Berber U, Yilmaz I, Narli G, Haholu A, Kucukodaci Z, Demirel D. Mir-205 and mir-200c: predictive micro RNAs for lymph node metastasis in triple negative breast cancer. J Breast Cancer. 2014;17:143–8.CrossRefPubMedPubMedCentral

21.

Chao CH, Chang CC, Wu MJ, Ko HW, Wang D, Hung MC, et al. Microrna-205 signaling regulates mammary stem cell fate and tumorigenesis. J Clin Invest. 2014;124:3093–106.CrossRefPubMedPubMedCentral

22.

Sun EH, Zhou Q, Liu KS, Wei W, Wang CM, Liu XF, et al. Screening miRNAs related to different subtypes of breast cancer with miRNAs microarray. Eur Rev Med Pharmacol Sci. 2014;18:2783–8.PubMed

23.

Elgamal OA, Park JK, Gusev Y, Azevedo-Pouly AC, Jiang J, Roopra A, et al. Tumor suppressive function of mir-205 in breast cancer is linked to HMGB3 regulation. PLoS One. 2013;8:e76402.CrossRefPubMedPubMedCentral

24.

Markou A, Yousef GM, Stathopoulos E, Georgoulias V, Lianidou E. Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up. Clin Chem. 2014;60:197–205.CrossRefPubMed

25.

Wang Z, Liao H, Deng Z, Yang P, Du N, Zhanng Y, et al. Mirna-205 affects infiltration and metastasis of breast cancer. Biochem Biophys Res Commun. 2013;441:139–43.CrossRefPubMed

26.

Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, et al. Mir-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 2009;69:2287–95.CrossRefPubMed

27.

Hagman Z, Haflidadottir BS, Ceder JA, Larne O, Bjartell A, Lilja H, et al. Mir-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer. 2013;108:1668–76.CrossRefPubMedPubMedCentral

28.

Chen Z, Tang ZY, He Y, Liu LF, Li DJ, Chen X. Mirna-205 is a candidate tumor suppressor that targets ZEB2 in renal cell carcinoma. Oncol Res Treat. 2014;37:658–64.CrossRefPubMed

29.

Majid S, Saini S, Dar AA, Hirata H, Shahryari V, Tanaka Y, et al. MicroRNA-205 inhibits SRC-mediated oncogenic pathways in renal cancer. Cancer Res. 2011;71:2611–21.CrossRefPubMedPubMedCentral

30.

Dar AA, Majid S, de Semir D, Nosrati M, Bezrookove V, Kashani-Sabet M. Mirna-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem. 2011;286:16606–14.CrossRefPubMedPubMedCentral

31.

Xu Y, Brenn T, Brown ER, Doherty V, Melton DW. Differential expression of micrornas during melanoma progression: mir-200c, mir-205 and mir-211 are downregulated in melanoma and act as tumour suppressors. Br J Cancer. 2012;106:553–61.CrossRefPubMedPubMedCentral

32.

Lei L, Huang Y, Gong W. Mir-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol Rep. 2013;30:2897–902.PubMed

33.

Cai J, Fang L, Huang Y, Li R, Yuan J, Yang Y, et al. Mir-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res. 2013;73:5402–15.CrossRefPubMed

34.

Vosa U, Vooder T, Kolde R, Vilo J, Metspalu A, Annilo T. Meta-analysis of microRNA expression in lung cancer. Int J Cancer J Int du cancer. 2013;132:2884–93.CrossRef

35.

Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF, et al. Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer J Int du cancer. 2009;124:1358–65.CrossRef

36.

Su N, Qiu H, Chen Y, Yang T, Yan Q, Wan X. Mir-205 promotes tumor proliferation and invasion through targeting ESRRG in endometrial carcinoma. Oncol Rep. 2013;29:2297–302.PubMed

37.

Tian L, Zhang J, Ge J, Xiao H, Lu J, Fu S, et al. Microrna-205 suppresses proliferation and promotes apoptosis in laryngeal squamous cell carcinoma. Med Oncol. 2014;31:785.CrossRefPubMed

38.

Yu J, Ryan DG, Getsios S, Oliveira-Fernandes M, Fatima A, Lavker RM. MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. Proc Natl Acad Sci U S A. 2008;105:19300–5.CrossRefPubMedPubMedCentral

39.

Redova M, Poprach A, Besse A, Iliev R, Nekvindova J, Lakomy R, et al. Mir-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tum Biology J Int Soc Oncod Biol Med. 2013;34:481–91.CrossRef

40.

Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. Bioinformatics. 2010;26:2363–7.CrossRefPubMedPubMedCentral

41.

Team RC. A language and environment for statistical computing. R foundation for statistical computing, vienna, austria; 2013. Url http://www.R-project.Org/.

42.

Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. Microrna expression profiles classify human cancers. Nature. 2005;435:834–8.CrossRefPubMed

43.

Kimura S, Naganuma S, Susuki D, Hirono Y, Yamaguchi A, Fujieda S, et al. Expression of microRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers for HNSCC and ESCC. Oncol Rep. 2010;23:1625–33.PubMed

44.

Li K, Yao L, Chen L, Cao ZG, Yu SJ, Kuang XY, et al. Id2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits e-cadherin expression. OncoTargets Ther. 2014;7:1083–94.

45.

Allegra M, Zaragkoulias A, Vorgia E, Ioannou M, Litos G, Beug H, et al. Semaphorin-7a reverses the ERF-induced inhibition of EMT in Ras-dependent mouse mammary epithelial cells. Mol Biol Cell. 2012;23:3873–81.CrossRefPubMedPubMedCentral

46.

Nam EJ, Lee M, Yim GW, Kim JH, Kim S, Kim SW, et al. Microrna profiling of a cd133(+) spheroid-forming subpopulation of the ovcar3 human ovarian cancer cell line. BMC Med Genet. 2012;5:18.

47.

Greene SB, Gunaratne PH, Hammond SM, Rosen JM. A putative role for microrna-205 in mammary epithelial cell progenitors. J Cell Sci. 2010;123:606–18.CrossRefPubMedPubMedCentral

48.

Du X, Lin BC, Wang QR, Li H, Ingalla E, Tien J, et al. Mmp-1 and pro-mmp-10 as potential urinary pharmacodynamic biomarkers of fgfr3-targeted therapy in patients with bladder cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20:6324–35.CrossRef

Title: MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus
Authors: Renata Hezova
Alena Kovarikova
Josef Srovnal
Milada Zemanova
Tomas Harustiak
Jiri Ehrmann
Marian Hajduch
Milana Sachlova
Marek Svoboda
Ondrej Slaby
Publication date: 01-06-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4656-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients

Sphingosine kinase 2 promotes colorectal cancer cell proliferation and invasion by enhancing MYC expression

Association of estrogen and progesterone receptor gene polymorphisms and their respective hormones in uterine leiomyomas

A novel and selective inhibitor of PKC ζ potently inhibits human breast cancer metastasis in vitro and in mice

Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma

Silencing stem cell factor attenuates stemness and inhibits migration of cancer stem cells derived from Lewis lung carcinoma cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer